Whole Body PET-MRI in Paediatric and Adolescent Lymphoma
PET/MRI
Feasibility of Using Whole Body PET-MRI to Stage and Restage Paediatric and Adolescent Hodgkin Lymphoma - a Pilot Study
1 other identifier
observational
25
1 country
1
Brief Summary
Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment. Investigators want to investigate if a combined PET-MRI scan could give the same information. Children who join our study will have an extra scan twice during their treatment
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2014
CompletedFirst Submitted
Initial submission to the registry
December 3, 2015
CompletedFirst Posted
Study publicly available on registry
October 17, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedOctober 17, 2016
December 1, 2015
3.2 years
December 3, 2015
October 13, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
The investigator will determine the technical feasibility of performing functional co-registered combined PET-MRI in this patient group using diffusion-weighted MR imaging.
3 years
Interventions
Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
Eligibility Criteria
Childhood and adolescent cases of clinically suspected or histologically confirmed Hodgkin Lymphoma
You may qualify if:
- Suspected or histologically confirmed Hodgkin lymphoma
- Male or female participants
- Age 0-20 years inclusive
- Entered into the EuroNet PHL-C1 trial, LP1 trial or successor Euronet trials, including Euronet PHL C2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial.
- Participant/Guardian/Parental written informed consent
You may not qualify if:
- Participants with contraindications to MRI (including cardiac pacemakers or non-MRI compatible intracranial vascular clips)
- Participants who are pregnant or nursing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre for Medical Imaging
London, London, NW1 2PG, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paul Humphries
UCL
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 3, 2015
First Posted
October 17, 2016
Study Start
February 1, 2014
Primary Completion
May 1, 2017
Study Completion
May 1, 2017
Last Updated
October 17, 2016
Record last verified: 2015-12
Data Sharing
- IPD Sharing
- Will share